Parley Neurotech

Cover Block

Company	Parley Neurotech
Tagline	Treatment for age-related central auditory processing disorder via repurposed drug + sound protocol
Headquarters	Denver, CO
Founded	2025
Stage	Pre-Seed
Business Model	Other
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Links

• Website: https://www.parley-neuro.com/
• LinkedIn: https://www.linkedin.com/company/parley-neurotech-inc

Executive Summary

Parley Neurotech is developing a first-in-class treatment for age-related central auditory processing disorder, a prevalent and under-addressed brain-based hearing deficit positioned as a major modifiable risk factor for dementia [CU Anschutz Medical School, 2024]. The company's LOOT therapy combines a repurposed, FDA-approved drug with a proprietary sound-stimulation protocol, aiming to remyelinate and repair neural circuits rather than simply amplify sound [CU Anschutz Medical School, 2024]. Founded in 2025 as a spinout from the University of Colorado Anschutz, the venture is built on foundational science from the Klug Lab and has already initiated a Phase I/IIa clinical trial [CU Anschutz Medical School, 2024].

The founding team pairs deep academic and translational expertise. CEO Sam Budoff holds a PhD in Neuroscience from CU Anschutz and has prior biotech founding experience, while CSO Achim Klug is the CU Anschutz professor whose lab originated the core science [CU Anschutz Medical School, 2024]. Capitalization is not publicly disclosed; the company has received support from the university's SPARK CU Innovations program and has joined the Innosphere Ventures incubator [F6S, 2024]. The business model remains clinical-stage, with revenue generation contingent on successful trial outcomes and eventual regulatory approval.

Over the next 12-18 months, the critical milestones are the progression and initial data readouts from the ongoing CAPD-LOOT trial, which will provide the first clinical validation of the combination therapy's safety and efficacy. Investors should also watch for the company's ability to attract its first institutional venture capital round to fund the lengthy and capital-intensive neurotherapeutic development pathway.

Data Accuracy: YELLOW -- Core product and team facts are confirmed by university sources; funding and financial metrics lack independent public corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Other
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

How the Company Got Here

Parley Neurotech is a clinical-stage neurotechnology spinout from the University of Colorado Anschutz Medical Campus, founded in 2025 and headquartered in Denver, Colorado [F6S, 2024]. The company was formed to commercialize a novel combination therapy, known as LOOT, which targets age-related central auditory processing disorder (CAPD), a brain-based hearing deficit with no current FDA-approved treatment [CU Anschutz Physiology, 2024].

Its founding is directly tied to the scientific work of co-founder Achim Klug, a professor at CU Anschutz whose lab originated the underlying science [CU Anschutz Physiology, 2024]. The university's technology transfer arm, CU Innovations, licensed the LOOT technology to the startup, with Klug's postdoctoral researcher, Sam Budoff, named as co-founder and CEO [CU Innovations, 2024]. A key early milestone was the company's acceptance into the Innosphere Ventures incubator program in Fort Collins, Colorado [LinkedIn].

Operational progress is currently defined by clinical trial initiation. In 2024, Parley Neurotech enrolled the first volunteer in a double-blind, placebo-controlled Phase I/IIa study (NCT07304024) for its therapy [CU Anschutz Physiology, 2024].

Data Accuracy: YELLOW -- Core founding and licensing narrative is confirmed by university sources; operational details are limited to a single public source.

Product and Technology

The core product is an investigational combination therapy, known as LOOT in the clinical context, targeting age-related central auditory processing disorder (CAPD). The approach is defined by its two-component architecture: a repurposed, FDA-approved drug and a proprietary sound-stimulation protocol [CU Anschutz Medical School, 2024]. The company's public positioning frames this as a first-in-class attempt to reverse a brain-based hearing deficit, moving beyond amplification to neural repair [Parley Neurotech]. The drug component, described only as being over 50 years old, is intended to support remyelination and neural circuit repair, while the engineered sound protocol is designed to target and stimulate the specific central auditory pathways affected by age-related decline [CU Anschutz Medical School, 2024].

Public details on the specific technology stack are limited. The company is a clinical-stage spinout, and its primary technical asset is the licensed intellectual property covering the LOOT combination from the University of Colorado Anschutz [CU Innovations, 2024]. The therapy's initial and only documented deployment is within a registered clinical trial (NCT07304024), a double-blind, placebo-controlled Phase I/IIa study, which enrolled its first volunteer in 2024 [CU Anschutz Medical School, 2024].

The market for age-related central auditory processing disorder (CAPD) is significant not because of a current commercial footprint, but because it represents a large, unaddressed risk factor for dementia, a condition with immense societal and economic costs. Parley Neurotech's pitch positions CAPD as "the single largest modifiable risk factor for dementia," citing the Lancet Commission on dementia risk factors [CU Anschutz Medical School, 2024].

Quantifying the addressable population is the first step. The company claims CAPD affects 1 in 3 people over 40 and half of those over 65 [F6S, 2024]. For context, the U.S. Census Bureau estimated approximately 134 million adults aged 40 and over in 2023. Using the company's lower bound (33%), this suggests a domestic prevalence pool exceeding 44 million individuals.

Metric	Value
Hearing Aids Market 2023	$10.2B
Hearing Aids Market 2032 (projected)	$18.9B
Brain Health Market 2023	$6.7B

Data Accuracy: YELLOW -- Market size claims are company-sourced; adjacent market figures are from third-party analyst reports. The dementia risk linkage is cited from a reputable medical journal commission via university coverage.

Competitive Landscape

Parley Neurotech enters a hearing health market defined by a clear gap: the absence of any FDA-approved treatment for its specific target, age-related central auditory processing disorder (CAPD).

• Direct Pharmacological Competitors. Few companies are developing drugs for central auditory processing deficits. Frequency Therapeutics, which pursued hair-cell regeneration for sensorineural hearing loss, halted its lead program in 2023 after Phase II failures [Fierce Biotech, October 2023]. Decibel Therapeutics, also focused on hearing restoration, has shifted its pipeline toward gene therapies for congenital hearing loss [Decibel Therapeutics, 2024].
• Hearing Aid & Cochlear Implant Incumbents. Companies like Sonova (Phonak), Demant (Oticon), and Cochlear dominate the hearing device market. These address amplification and severe-to-profound hearing loss but do not claim to treat the brain-based signal processing deficit of CAPD.
• Adjacent Cognitive & Longevity Interventions. The company's framing of CAPD as a modifiable dementia risk factor places it adjacent to a broader brain health market.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Parley Neurotech	First treatment for age-related CAPD via drug+sound protocol	Pre-Seed / University program support	Targets neural circuit repair (remyelination); no FDA-approved alternative exists	[CU Anschutz Physiology, 2024]
Frequency Therapeutics	Hair-cell regeneration for sensorineural hearing loss	Public / ~$100M raised (estimated)	Focused on peripheral hearing restoration via progenitor cell activation; lead program discontinued	[Fierce Biotech, October 2023]
Decibel Therapeutics	Gene therapy for congenital hearing loss	Public / ~$250M raised (estimated)	AAV-based therapies targeting specific genetic mutations; pipeline does not address age-related CAPD	[Decibel Therapeutics, 2024]

Data Accuracy: YELLOW -- Competitor profiles and funding are confirmed via public filings and news; Parley's specific differentiation is sourced from university materials. The competitive mapping and scenario analysis are analyst inferences based on the available public data.

Opportunity

Parley Neurotech's opportunity is to build a category-defining neurotherapeutic platform by proving that a repurposed drug and sound protocol can reverse a specific, age-related brain deficit, thereby unlocking a path to treating a major modifiable risk factor for dementia.

The headline opportunity is to become the first FDA-approved therapy for central auditory processing disorder, a condition the company positions as affecting one in three people over 40 and half of those over 65 [F6S, 2024]. The ongoing Phase I/IIa trial, which recently enrolled its first volunteer, is the critical first step in validating this approach in humans [CU Anschutz Physiology, 2024].

Scenario	What happens	Catalyst	Why it's plausible
The Dementia Prevention Wedge	LOOT's approval for CAPD becomes a gateway to larger trials for dementia prevention, supported by longitudinal data linking hearing loss to cognitive decline.	Publication of positive trial data showing improved auditory processing and correlated cognitive biomarkers.	The company's own materials cite the Lancet Commission on dementia risk factors, framing CAPD as "the single largest modifiable risk factor for dementia" [CU Anschutz Physiology, 2024].
The Neuroregeneration Platform	The validated drug+sound protocol is adapted to treat other age-related central processing deficits, such as in vision or balance, leveraging the same core remyelination science.	A partnership with a larger pharma company to fund exploratory research in adjacent neural circuits.	The underlying mechanism targets neural circuit repair, a principle not limited to the auditory system.

Data Accuracy: YELLOW -- Opportunity framing relies on company-cited epidemiology and a clear clinical pathway, but market comparables are inferred from adjacent sectors.

Sources

1. [CU Anschutz Medical School, 2024] Parley Neurotech | https://medschool.cuanschutz.edu/physiology/news/parley-neurotech
2. [CU Anschutz Physiology, 2024] Parley Neurotech | https://medschool.cuanschutz.edu/physiology/news/parley-neurotech
3. [F6S, 2024] Parley Neurotech | https://www.f6s.com/company/parley-neurotech
4. [CU Innovations, 2024] A First-of-its-kind Treatment for Brain-Based Hearing Loss | https://news.cuanschutz.edu/cu-innovations/first-of-its-kind-treatment-for-brain-based-hearing-loss
5. [Parley Neurotech] Parley Neurotech - The Future of Hearing is Neural | https://www.parley-neuro.com/
6. [LinkedIn] Parley Neurotech, Inc. | https://www.linkedin.com/company/parley-neurotech-inc
7. [Fierce Biotech, October 2023] Frequency Therapeutics halts hearing loss trial, cuts staff | https://www.fiercebiotech.com/biotech/frequency-therapeutics-halts-hearing-loss-trial-cuts-staff
8. [Decibel Therapeutics, 2024] Decibel Therapeutics Pipeline | https://www.decibeltx.com/pipeline/
9. [Klug Lab] Welcoming Dr. Sam Budoff: Bridging Spatial Vision and Spatial Hearing | https://www.kluglab.org/hearing-loss-blog/welcoming-dr-sam-budoff-bridging-spatial-vision-and-spatial-hearing